The research, led by Amr A. Amin of Umm Al-Qura University in Makkah, Saudi Arabia, together with colleagues at Ain-Shams University in Cairo, focused on two single-nucleotide polymorphisms in the IL-10 gene on chromosome 1, designated rs1518111 and rs1554286. Rather than treating each variant in isolation, the team reconstructed how the two SNPs are inherited together as haplotypes and diplotypes—paired combinations of haplotypes on the two copies of chromosome 1. This multilocus approach matters because nearby variants that travel together, a phenomenon known as linkage disequilibrium, can obscure or exaggerate the apparent effect of any single variant when analyzed alone.

The study enrolled consecutive adults meeting the Sepsis-3 criteria in the intensive care units of a tertiary care medical center between August 2023 and September 2025. Blood and 24-hour urine samples were collected within 24 hours of sepsis confirmation, and genotyping was performed using TaqMan allelic discrimination assays with rigorous quality control: blinded laboratory staff, negative controls, and replicate testing of random sample subsets with complete concordance. Of the 492 patients, 84—about 17 percent—progressed to septic shock, defined as persistent hypotension requiring vasopressors to maintain a mean arterial pressure of at least 65 mmHg together with a serum lactate above 2 mmol/L despite adequate fluid resuscitation.

The genetic findings were striking. The two variants showed near-complete linkage disequilibrium, with a D′ of 1.00 and an r² of 0.903, meaning they are almost always inherited as a single block. When the researchers grouped patients by diplotype and adjusted for age, sex, admission white blood cell count, and baseline SOFA score, a clear pattern emerged. Patients homozygous for the variant T-A haplotype carried roughly 6.3-fold higher odds of progressing to septic shock compared with the heterozygous reference configuration, while those homozygous for the wild-type C-G haplotype showed dramatically lower odds—an adjusted odds ratio of 0.28, indicating a strongly protective profile. The allele frequency data underscore the disparity: among patients who developed shock, the minor allele frequency at both loci reached 0.785, compared with roughly 0.3 in patients whose sepsis remained hemodynamically stable.

Crucially, the genetic risk profile was not an abstract statistical construct—it tracked directly with measurable physiology. Homozygous variant carriers at either locus had the highest concentrations of IL-10 in both serum and urine, with median serum levels exceeding 214 pg/mL versus roughly 165 pg/mL in wild-type carriers, and they also exhibited significantly lower systolic and diastolic blood pressures. Heterozygous carriers, by contrast, resembled the wild-type group on both counts, a pattern consistent with a recessive mode of inheritance. Septic shock patients overall showed elevated serum IL-10 (median 193.9 pg/mL versus 169.4 pg/mL) and urinary IL-10 (20.8 versus 17.2 pg/mL) compared with non-shock patients, suggesting a coordinated counter-regulatory immune response spanning both systemic and renal compartments.

The biology behind this pattern is complex and, at first glance, paradoxical. Interleukin-10 is essential for reining in the inflammatory cascade during infection, preventing the collateral tissue destruction caused by unchecked cytokine amplification. But excessive or prolonged IL-10 expression can push patients into immunoparalysis—a state of immune suppression that may heighten susceptibility to secondary infections and mortality. The new findings hint that inherited variation within the IL-10 locus may tilt patients toward one end of this immunological spectrum, predisposing some individuals to an exaggerated anti-inflammatory response that coincides with hemodynamic deterioration. The authors are careful to note that the association between genotype, cytokine levels, and low blood pressure does not establish causation; the cross-sectional cytokine measurements cannot determine whether elevated IL-10 preceded, accompanied, or resulted from the onset of shock.

The team also explored whether these biomarkers could discriminate which patients would deteriorate. Serum IL-10 alone performed best among individual markers, achieving an area under the receiver operating characteristic curve of 0.851; at a threshold of 210 pg/mL it detected 95.2 percent of septic shock cases with 69.6 percent specificity and a negative predictive value of 98.6 percent. A combined clinical-genetic model integrating serum IL-10, admission white blood cell count, and diplotype category pushed the AUC to 0.889 (95 percent confidence interval, 0.820–0.958), with the same high sensitivity and 72.5 percent specificity. Urinary IL-10 and white blood cell count alone were more modest, with AUCs of 0.736 and 0.744 respectively.

Important caveats temper the enthusiasm. The performance estimates were derived and evaluated within the same cohort, without bootstrap correction, cross-validation, or external validation, so they likely represent an optimistic ceiling. The study was also single-center, and allele frequencies and linkage disequilibrium patterns can vary substantially across ancestries—a particular concern given that Middle Eastern populations remain underrepresented in genomic reference resources, a gap the authors cite as motivation for their work. IL-10 was measured at only a single early time point, precluding analysis of cytokine trajectories, and the panel did not include other established inflammatory and perfusion markers such as IL-6, procalcitonin, monocyte HLA-DR, or serial lactate. The authors also observed deviations from Hardy–Weinberg equilibrium within the non-shock reference group, which they interpreted cautiously given that disease-associated cohorts frequently deviate from HWE because of risk-allele enrichment.

Notably, this is not the first time rs1518111 has surfaced in the team’s work. An earlier study, conducted in a completely independent cohort recruited between 2016 and 2018, linked the same variant and paired serum and urinary IL-10 measurements to sepsis-associated acute kidney injury. The recurrence of rs1518111 across two clinically distinct severe-sepsis phenotypes strengthens the rationale for continued investigation, even though the two outcomes are not interchangeable and cannot be assumed to share a common causal pathway.

For now, the message is one of promise rather than prescription. The authors explicitly caution that IL-10 genotyping should not yet be used to guide vasopressor selection or any bedside treatment decisions, and they emphasize that their combined model is hypothesis-generating pending validation in larger, multicenter, multi-ethnic cohorts with serial biomarker measurements and functional studies of the implicated variants. If those efforts succeed, the vision is compelling: a rapid genetic and biochemical fingerprint, obtainable within the first day of ICU admission, that flags which sepsis patients carry the highest risk of circulatory collapse—turning septic shock from a sudden catastrophe into a foreseeable event that clinicians can anticipate, monitor, and perhaps preempt.

Subject of Research: Association of IL-10 gene haplotypes and diplotypes with septic shock susceptibility, cytokine expression, and hemodynamic dysfunction in critically ill patients

Article Title: IL-10 diplotype and septic shock: Genotype–Phenotype associations with hemodynamic dysfunction and IL-10 expression

Article References: Amin, A. A., Althubiti, M., Fatani, S. H., Mufti, A. H., Azher, Z. A., Malibari, G. M., & Bogari, N. M. (2026). IL-10 diplotype and septic shock: Genotype–Phenotype associations with hemodynamic dysfunction and IL-10 expression. Frontiers in Molecular Biosciences, 13, Article 1958117. https://doi.org/10.3389/fmolb.2026.1958117

Image Credits: AI Generated

DOI: 10.3389/fmolb.2026.1958117

Keywords: sepsis, septic shock, interleukin-10, IL-10 gene polymorphisms, haplotype, diplotype, linkage disequilibrium, genetic association study, biomarkers, hemodynamic dysfunction, cytokine expression, critical care

Writing in Nature, the group describes a myeloid-selective interleukin-10 receptor agonist, or msIL-10R agonist, a tetravalent nanobody-based molecule that reproduces IL-10’s potent suppression of inflammatory myeloid cells while leaving T cells untouched. The key insight came from a careful dissection of how different immune cells transmit the IL-10 signal. IL-10 normally binds IL-10Rα and IL-10Rβ to form a tetrameric receptor complex constitutively associated with the Janus kinases JAK1 and TYK2. When the cytokine engages the receptor, JAK1 must be activated through transphosphorylation, and the team found that cells can accomplish this through two parallel routes: TYK2-to-JAK1 or JAK1-to-JAK1. Crucially, the relative reliance on these routes differs dramatically between cell types.

To map these routes, the researchers used a selective allosteric JAK1 inhibitor called VVD-118313, which blocks JAK1 transphosphorylation without touching the kinase’s active site, alongside the TYK2 inhibitor zasocitinib and CRISPR-based gene knockout. In mouse bone-marrow-derived macrophages, blocking JAK1-to-JAK1 transphosphorylation only partially reduced IL-10-induced STAT3 phosphorylation and did not abolish the cytokine’s functional suppression of tumour necrosis factor. Only when TYK2 was also removed did signalling collapse completely, showing that at least one transphosphorylation route must remain intact. Human monocytes behaved similarly: TYK2 inhibition or knockout dented STAT3 phosphorylation but left the suppression of LPS-induced TNF and IL-6 fully intact.

T cells told a strikingly different story. In CD8-positive T cells, both pharmacological TYK2 inhibition and CRISPR knockout diminished IL-10-induced STAT3 phosphorylation and completely eliminated the cytokine’s augmentation of granzyme B and interferon-gamma production. T cells, in other words, depend strictly on TYK2 and on maximal pathway activation, whereas myeloid cells tolerate a substantially attenuated signal. The team confirmed this threshold logic with an engineered IL-10 monomer that engages only a single IL-10Rα–IL-10Rβ heterodimer, restricting signalling to one TYK2–JAK1 route. The monomer drove roughly half of maximal STAT3 phosphorylation in monocytes yet retained meaningful TNF suppression, while failing entirely to activate STAT3 or cytotoxic effector programs in T cells. Attenuation, it seemed, could be a feature rather than a bug.

Attenuated cytokines alone, however, make poor drugs. Previous IL-10 monomers and affinity-tuned muteins suffered from short half-lives, thermal instability, residual T and B cell activation and vulnerability to naturally occurring anti-IL-10 autoantibodies, which are common in inflammatory bowel disease. The team instead turned to single-domain antibodies. Alpacas were immunized with the extracellular domains of human IL-10Rα and IL-10Rβ, and phage-display libraries built from their B cells yielded diverse families of receptor-binding VHH domains. These were assembled into dimeric and tetravalent constructs pairing anti-IL-10Rα with anti-IL-10Rβ nanobodies, and screened in STAT3 reporter cells and primary human cells. Of 882 combinations tested, 182 showed reporter activity and 21 achieved more than 90 percent inhibition of TNF and more than 85 percent inhibition of IL-6 in LPS-stimulated blood cells.

Most of those hits, however, still recapitulated IL-10’s unwanted T cell stimulation. One construct stood apart. Designated the msIL-10R agonist, it pairs an anti-IL-10Rα nanobody called E07 with an anti-IL-10Rβ nanobody called A05 in each arm of an Fc scaffold, creating a tetravalent molecule with picomolar potency. It inhibited LPS-induced TNF with a half-maximal inhibitory concentration of 2.1 picomolar and IL-6 at 6.9 picomolar in human blood cells, while eliciting less than 10 percent of maximal STAT3 phosphorylation in CD4 and CD8 T cells, no induction of interferon-gamma or granzyme B, and no B cell proliferation or plasmablast differentiation. RNA sequencing confirmed that the molecule reproduced IL-10’s anti-inflammatory transcriptional program in resting and LPS-stimulated blood cells, including suppression of CSF3, IL6 and PTGES, yet induced no significantly differentially expressed genes in activated T cells.

Cryo-electron microscopy revealed why geometry matters so much. Using a fiducial Fab to enlarge the small receptor–nanobody complex, the team resolved the IL-10Rα–IL-10Rβ–E07-A05 assembly at 3.14 angstroms and a second IL-10Rα–E07 complex at 2.40 angstroms. The nanobody A05 binds an epitope on IL-10Rβ that partially overlaps the cytokine-binding surface but induces a local rearrangement of the Asn138–Trp143 loop, while E07 recognizes a broad surface spanning the junction of IL-10Rα’s two fibronectin type III domains, on the opposite side of the receptor from the IL-10 binding site. Notably, disease-associated IL10RA mutations such as Y64C and R117C, which cripple native IL-10 signalling and underlie very-early-onset inflammatory bowel disease, left the msIL-10R agonist’s activity fully intact, because the molecule engages epitopes spatially distinct from the cytokine interface.

Functional dissection showed that the tetravalent architecture is not negotiable. Disrupting either receptor-binding arm abolished STAT3 phosphorylation and cytokine suppression, maximal activity required simultaneous cross-linking of two IL-10Rα molecules with one or two IL-10Rβ molecules, and even subtle geometric changes were consequential. Shortening or lengthening the glycine-serine linker between E07 and A05 reduced activity, inverting the tandem nanobody order to A05-E07 abolished signalling entirely, and a symmetric A05-A05/E07-E07 arrangement boosted myeloid potency but restored roughly 20 percent of native IL-10’s interferon-gamma response in T cells. Signalling output, the authors conclude, is governed not simply by receptor occupancy but by the precise topology of receptor cross-linking, which forces the complex into a geometry that permits only TYK2-to-JAK1 transphosphorylation.

That strict TYK2 dependence, combined with receptor abundance, explains the selectivity. Myeloid cells express two- to eighteen-fold more surface IL-10Rα and IL-10Rβ than T, B or natural killer cells, providing the avidity needed to cluster the tetravalent agonist, whereas lymphocytes fall below the threshold. When the researchers forced T cells to overexpress IL-10Rα, and especially both receptor chains, STAT3 phosphorylation and granzyme B production returned, confirming receptor copy number as the critical determinant. The logic even proved portable: bispecific nanobodies pairing IL-10Rα with the lymphocyte-enriched IL-2Rγ chain redirected signalling toward T and NK cells, producing T/NK-selective agonists with minimal monocyte activity, again exquisitely dependent on geometry.

In vivo, the molecule delivered. In humanized IL10RA/IL10RB knock-in mice, it suppressed systemic TNF, IL-6 and IL-12 after LPS challenge as effectively as IL-10-Fc, reduced ear swelling and lymph node neutrophil infiltration in a delayed-type hypersensitivity model, and improved colon weight-to-length ratios, splenic neutrophil expansion and inflammatory gene expression in DSS-induced colitis. In cynomolgus monkeys, a humanized version showed dose-proportional exposure, sustained monocyte receptor occupancy and a terminal half-life of roughly eight days, with durable TNF suppression for more than three weeks after a single dose. Unlike IL-10-Fc, which elevated IL-18 and caused anaemia and thrombocytopaenia, the agonist produced no IL-18 elevation or haematological abnormalities at doses up to 100 milligrams per kilogram. The work establishes a geometry-based strategy for cell-type-selective cytokine engineering and positions the msIL-10R agonist as a promising candidate for inflammatory bowel disease and other myeloid-driven conditions, while offering a generalizable blueprint for precision cytokine therapeutics across immunology and oncology.

Subject of Research: Engineering a myeloid-selective IL-10 receptor agonist through TYK2-dependent signalling and receptor geometry

Article Title: Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism

Article References: Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism. (n.d.). https://doi.org/10.1038/s41586-026-11176-1

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11176-1

Keywords: interleukin-10, IL-10 receptor, TYK2, JAK1, nanobody, myeloid cells, T cells, STAT3, cryo-electron microscopy, inflammatory bowel disease, cytokine agonism, immunotherapy

The research team, led by investigators at Sohag and Assiut Universities, enrolled 40 patients with confirmed NSCLC and 40 age- and sex-matched healthy controls between January and December 2021. Patients underwent comprehensive staging, including chest and abdominal CT imaging, brain MRI or CT, bone scintigraphy, and fiber-optic bronchoscopy with biopsy. Disease extent was classified using the American Joint Committee on Cancer’s eighth-edition TNM system: five patients had stage II disease, fifteen had stage III, and twenty had stage IV, with regional lymph node metastasis present in twenty individuals. Histopathology revealed nineteen adenocarcinomas, fourteen squamous cell carcinomas, four undifferentiated carcinomas, and three large cell carcinomas.

Using multicolor flow cytometry, the researchers quantified circulating lymphocyte subsets with considerable technical precision. Tregs were identified as CD4-positive T cells co-expressing high levels of CD25 and the master transcription factor Foxp3, a combination that marks the most suppressive regulatory population. Bregs were defined as CD19-positive B cells expressing high levels of both CD24 and CD38 — the so-called immature or transitional B cell phenotype, which is known to secrete copious amounts of the anti-inflammatory cytokine interleukin-10. Fluorescence-activated cell sorting with isotype controls and mean fluorescence intensity measurements allowed the team to distinguish these rare regulatory populations from conventional lymphocytes with confidence.

The results were unambiguous. Compared with healthy controls, NSCLC patients showed significantly higher frequencies of CD8-positive cytotoxic T cells, CD4-positive CD25-high T cells, Foxp3-expressing Tregs, and Bregs, along with a significantly reduced CD4-to-CD8 ratio — a signature often interpreted as chronic immune perturbation. Notably, total CD19-positive B cell numbers did not differ between groups, suggesting that the expansion was specific to the regulatory subset rather than a general B cell proliferation. The differences for Bregs and Tregs were statistically robust, with Breg elevation reaching a p-value of 0.0001.

Perhaps the most clinically provocative finding emerged when the researchers stratified patients by disease status. Those with distant metastases carried significantly higher frequencies of both Bregs and Tregs than patients whose disease had not spread beyond the chest. Both cell populations also rose significantly across TNM stages, with stage IV patients showing the highest levels, and both were significantly associated with histopathological subtype, peaking in adenocarcinoma. Intriguingly, the frequencies of the two regulatory populations correlated positively with each other, hinting at a coordinated regulatory axis rather than two independent phenomena.

That coordination makes biological sense. Prior work has shown that Bregs can promote the expansion and suppressive function of Tregs through direct cell-to-cell contact and through secretion of interleukin-10 and interleukin-35, upregulating Foxp3 and CTLA-4 in T cells. In the tumor microenvironment, Foxp3-positive Tregs can suppress cytotoxic T lymphocytes by interfering with the release of cytolytic granules, effectively disarming the body’s main tumor-killing weapon. The study’s authors argue that the elevated circulating Bregs and Tregs they observed likely mirror the same immunosuppressive axis documented inside tumors, and that blood-based measurement offers a non-invasive window into processes previously accessible only through tissue biopsy.

The cytokine data reinforce that interpretation. Using a multiplex Luminex assay, the team measured seven serum cytokines — interleukin-1 beta, interleukin-6, interleukin-17, tumor necrosis factor-alpha, interleukin-10, interleukin-35, and transforming growth factor-beta 1 — and found every one of them significantly elevated in patients compared with controls. Moreover, patients with distant metastases had significantly higher levels of all of these except interleukin-1 beta, and several cytokines, including interleukin-6, interleukin-17, tumor necrosis factor-alpha, interleukin-10, and TGF-beta 1, differed significantly across TNM stages. The pattern suggests a tumor-promoting inflammatory milieu in which pro-inflammatory and anti-inflammatory signals rise together, a paradoxical combination well described in cancer-related inflammation.

Each of these soluble mediators carries mechanistic weight. Interleukin-6 overexpression has repeatedly been linked to advanced stage and metastasis in lung cancer. Interleukin-17, produced by Th17 cells, exerts complex effects on tumor growth and spread. Interleukin-35, a relative newcomer to the interleukin-12 family, has been shown to drive CD8-positive T cell dysfunction and exhaustion, blunting antitumor immunity. TGF-beta 1 is among the most potent inducers of epithelial-mesenchymal transition in NSCLC cells, fueling invasion and metastatic potential, and several of these cytokines intersect with VEGF-mediated angiogenesis and vascular remodeling that support tumor expansion and immune exclusion.

The statistical picture is nuanced. In univariate logistic regression, higher Breg frequencies were inversely associated with lymph node involvement, and higher CD8 counts were linked to lower tumor grade, while an elevated CD4-to-CD8 ratio was positively associated with advanced grade. Yet when the researchers adjusted for multiple predictors simultaneously, none of the immune variables retained statistical significance — a result the authors attribute candidly to the modest sample size of forty patients, which limits statistical power. They emphasize that the consistent directionality of the effect estimates across models remains biologically plausible and aligned with established immunosuppressive mechanisms in NSCLC, and they call for validation in larger prospective cohorts.

The study has other acknowledged limitations. It included no stage I patients, reflecting a local reality in which most lung cancer cases in the region present at advanced stages, and its observational design establishes association rather than causation. Even so, the work’s central strength is compelling: a simple, non-invasive blood test that captures both the cellular and soluble arms of immune regulation and tracks them against disease stage and metastasis. If confirmed at scale, circulating Bregs, Tregs, and their cytokine signatures could become accessible surrogate biomarkers for the immunosuppressive tumor microenvironment — tools for monitoring disease progression, guiding immunotherapy decisions, and identifying patients whose regulatory immune networks are quietly helping their tumors hide.

Subject of Research: Association of circulating regulatory B cells, regulatory T cells, and serum cytokines with disease stage in non-small cell lung cancer

Article Title: Association of regulatory B, T cells and cytokine production with disease stage in non-small cell lung cancer patients: prospective case control study

Article References: Association of regulatory B, T cells and cytokine production with disease stage in non-small cell lung cancer patients: prospective case control study. (n.d.). https://doi.org/10.1186/s12885-026-16464-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16464-7

Keywords: non-small cell lung cancer, regulatory B cells, regulatory T cells, cytokines, flow cytometry, tumor immunology, metastasis, interleukin-10, interleukin-35, TGF-beta, biomarkers, immunosuppression

The condition in question, post-inflammatory wheezing, is a common and troubling sequel of acute pulmonary infection in young children. After an episode of severe pneumonia, many children continue to wheeze for weeks or months, a sign of persistent airway inflammation and dysfunction that can presage recurrent wheezing disorders and, in some children, the later development of asthma. Existing management is largely symptomatic, and the researchers behind the new study emphasize in their impact statement that there is currently no effective treatment specifically for post-inflammatory wheezing. Understanding why the airway stays inflamed after the initial infection has cleared is therefore a pressing question in pediatric respiratory medicine.

To address it, the team enrolled 239 children who had been hospitalized with severe pneumonia and divided them into two groups: those who went on to develop post-inflammatory wheezing and those who did not. The children with wheezing were then assigned to receive either routine symptomatic treatment alone or routine treatment plus a five-day course of azithromycin at a dose of 10 milligrams per kilogram of body weight per day. The researchers compared clinical outcomes between the groups and also examined cellular and molecular markers in bronchoalveolar lavage fluid, the liquid retrieved from the deep airways during fiberoptic bronchoscopy, which provides a direct window into the immunology of the lung.

The comparison revealed a distinctive inflammatory signature in the wheezing children. Their lavage fluid showed an abnormal cellular composition, elevated levels of the pro-inflammatory signaling molecule interleukin-6, and reduced levels of the anti-inflammatory cytokine interleukin-10, a pattern indicating that the immune balance of the airway had tipped toward attack rather than resolution. Crucially, the researchers also found significantly increased expression of SETD1B, a member of the SET domain family of histone methyltransferases, along with elevated levels of H3K4me3, the trimethylated form of histone H3 lysine 4 that SETD1B deposits. Histone modifications such as this one regulate which genes are accessible for transcription, meaning that the wheezing children’s airway immune cells appeared to be carrying an epigenetic imprint that kept inflammatory programs switched on.

When the children received azithromycin on top of routine care, the clinical benefits were clear. The drug shortened the duration of wheezing, reduced the length of hospital stay, and lowered medical costs compared with symptomatic treatment alone. Perhaps the most revealing result, however, came from a subgroup analysis. The researchers found no significant difference in clinical efficacy between children who tested positive for Mycoplasma pneumoniae, a bacterium that azithromycin can kill, and those who tested negative. If the drug were working purely as an antibiotic, mycoplasma-negative children should have derived little benefit. Instead, the benefit was equivalent in both groups, confirming that azithromycin’s therapeutic effect in post-inflammatory wheezing is independent of its anti-mycoplasma activity and must arise from some other property of the molecule.

That other property, the study suggests, is immunomodulation acting through the epigenetic machinery. Macrolide antibiotics like azithromycin have long been known to exert anti-inflammatory effects beyond their antimicrobial role, an observation that has fueled their use in chronic inflammatory airway diseases such as cystic fibrosis, diffuse panbronchiolitis, and chronic obstructive pulmonary disease, and that prompted intense interest in the drug during the COVID-19 pandemic. But the specific molecular targets of this immunomodulation have remained only partially mapped. The new work connects the drug to a precise epigenetic axis, and it builds on the same group’s earlier finding that azithromycin can attenuate wheezing by inhibiting a different histone mark, H3K27me3, mediated by the enzyme EZH2, suggesting that the drug’s anti-inflammatory reach extends across multiple histone methylation systems.

To test the mechanism directly, the researchers turned to an in vitro model. They exposed rat alveolar macrophages, the resident immune cells of the lung’s air sacs, to lipopolysaccharide, a bacterial molecule that reliably triggers a strong inflammatory response. The LPS challenge induced hypermethylation of H3K4me3 driven by SETD1B, disturbed the production of inflammatory cytokines, and pushed the macrophages toward the M1 polarization state, the classically activated, pro-inflammatory phenotype that floods tissue with cytokines. Macrophage polarization, the process by which these cells shift between the inflammatory M1 state and the tissue-repairing M2 state, is increasingly recognized as a central player in inflammatory lung disease, and an excess of M1 polarization is a plausible driver of the persistent airway inflammation seen in wheezing children.

The decisive experiment involved comparing azithromycin with WDR5-0103, a small-molecule inhibitor that specifically blocks SETD1B function. When the LPS-stimulated macrophages were treated with either azithromycin or WDR5-0103 alone, the drug and the inhibitor each significantly reversed the full spectrum of LPS-induced abnormalities: the SETD1B-driven H3K4me3 hypermethylation, the cytokine imbalance, and the M1-skewed polarization. When the two were combined, however, no additional benefit emerged. This lack of synergy is mechanistically telling. If azithromycin and the SETD1B inhibitor were acting through separate pathways, combining them should have produced an additive effect. The absence of one indicates that the two interventions converge on the same target, placing SETD1B-mediated H3K4me3 methylation squarely on the pathway through which azithromycin exerts its anti-inflammatory effect in these cells.

Taken together, the clinical and laboratory findings sketch a coherent causal chain. Severe pulmonary infection elevates SETD1B expression in airway immune cells, which trims excess H3K4me3 marks onto histones near inflammatory genes, keeping them in a transcriptionally active state. This epigenetic drift biases alveolar macrophages toward the M1 phenotype, sustains high interleukin-6 output, suppresses interleukin-10, and maintains the airway in a state of chronic low-grade inflammation that manifests as wheezing. Azithromycin interrupts this chain at its epigenetic root, restoring the M1/M2 balance, normalizing the cytokine milieu, and allowing the airway inflammation to resolve, with the clinical result that children wheeze for less time and leave the hospital sooner.

The implications extend beyond a single drug and a single disease. The study demonstrates that a familiar, inexpensive, and well-characterized antibiotic can be repurposed as an epigenetic modulator for a pediatric condition with no current targeted treatment, and it identifies SETD1B and H3K4me3 as potential biomarkers for identifying which children with post-infectious wheezing carry an active epigenetic inflammatory program. It also raises questions that future work will need to answer, including whether the epigenetic changes seen in lavage fluid predict long-term asthma risk and whether shorter or longer azithromycin regimens might optimize the immunomodulatory effect while minimizing concerns about antibiotic resistance. For now, the study provides the strongest mechanistic account yet of why a five-day course of azithromycin can quiet a child’s wheezing long after the infection that started it has been cleared, and it suggests that the key to treating some chronic airway inflammation lies not in fighting microbes but in editing the inflammatory memory that immune cells carry within their chromosomes.

Subject of Research: Epigenetic and immunomodulatory mechanisms of azithromycin in pediatric post-inflammatory wheezing

Article Title: Azithromycin alleviates post-inflammatory wheezing in children by inhibiting SETD1B-mediated histone H3K4me3 methylation and macrophage polarization

Article References: Wang, L., Peng, C., Wu, S., Tang, T., Lin, Q., & Qin, H. (2026). Azithromycin alleviates post-inflammatory wheezing in children by inhibiting SETD1B-mediated histone H3K4me3 methylation and macrophage polarization. Pediatric Research. https://doi.org/10.1038/s41390-026-05444-z

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05444-z

Keywords: azithromycin, post-inflammatory wheezing, SETD1B, H3K4me3, histone methylation, macrophage polarization, alveolar macrophages, interleukin-6, interleukin-10, pediatric pneumonia, epigenetics, immunomodulation

Regulatory B cells, or Bregs, are a subset of B lymphocytes defined less by a single surface marker than by what they secrete. Their signature products are the immunosuppressive cytokines interleukin-10, interleukin-35 and transforming growth factor beta. Through these molecules, Bregs restrain effector immune responses, reining in the very CD8-positive T cells that checkpoint blockade drugs such as nivolumab and ipilimumab are designed to unleash against tumours. This creates what the authors describe as a fundamental tension: the same interleukin-10 programme that protects patients from the collateral inflammation of immunotherapy also dampens the tumour-directed cytotoxic response that the therapy depends upon. Understanding how Bregs are generated, where they accumulate and what feeds their suppressive machinery therefore has direct implications for predicting and manipulating responses to checkpoint inhibitors.

The review anchors the microbiome-Breg relationship in two mechanistic axes. The first is a cytokine-driven pathway. Gut commensal bacteria stimulate myeloid cells to produce interleukin-1 beta and interleukin-6, which act on matching receptors on B cells. This signalling drives the differentiation of B cells into interleukin-10-competent regulatory cells in the spleen and mesenteric lymph nodes, the lymphoid tissues that drain the intestine. In other words, the microbial ecology of the gut supplies the inflammatory context that teaches B cells to become suppressive. The second axis is metabolic rather than cytokinic: microbially derived short-chain fatty acids, principally butyrate, amplify aryl hydrocarbon receptor signalling within Bregs. Notably, this route increases the suppressive capacity of individual Bregs rather than expanding their numbers, meaning the gut can tune the potency of the regulatory compartment without changing its size.

To connect intestinal biology with tumour immunology, the authors adopt the gut-lung axis as their organising framework. This concept, well established in respiratory research, holds that microbial products and immune cells primed in the gut can influence immune responses in the lung. Because lung cancer, particularly non-small cell lung cancer, is one of the flagship indications for checkpoint blockade, the framework matters clinically. The review is careful, however, to separate evidence generated directly in cancer models from data drawn from autoimmune and inflammatory disease research, an important distinction because Breg biology studied in lupus or colitis may not translate cleanly to the tumour microenvironment.

Four testable gaps emerge from the synthesis, each of which could shape the next decade of research. First, it remains unknown whether gut-induced Bregs actually traffic to lung tumours or their draining lymph nodes, a question that could be addressed with lineage tracing and parabiosis-style experiments. Second, the authors ask whether lung-resident commensal bacteria can generate lung-resident Bregs, mirroring what has been described in the pancreas, where local commensals drive epithelial cells to produce interleukin-1 beta and thereby shape the local immune landscape. Third, they highlight the possibility that microbiota-selected B cell receptor clonotypes feed the Breg pool, implying that the antigen specificity of regulatory B cells is not random but curated by the microbial environment. Fourth, and most relevant to human disease, the metabolic programme that sustains Bregs within human tumours has not been defined, leaving a gap between mouse mechanistics and clinical application.

The clinical stakes are illustrated by striking results from microbiome-targeted interventions. Faecal microbiota transplantation from healthy donors, performed before checkpoint blockade, produced objective response rates of 80 percent in first-line non-small cell lung cancer and 75 percent in melanoma in the studies reviewed. These figures far exceed the response rates typically achieved with checkpoint inhibitors alone in these settings, suggesting that reshaping the microbial environment can meaningfully reprogramme antitumour immunity. Separately, the live biotherapeutic CBM588, a strain of Clostridium beijerinckii, added to nivolumab and ipilimumab in renal cell carcinoma yielded a progression-free survival hazard ratio of 0.15, with a 95 percent confidence interval of 0.05 to 0.47, indicating a substantial reduction in the risk of progression or death compared with checkpoint blockade alone.

How might these dramatic effects connect to Bregs? The review’s mechanistic framework offers a plausible chain of causation. Transplanted or probiotic microbes alter the cytokine and metabolite milieu of the gut, changing the signals that drive Breg differentiation and potency. A gut environment rich in butyrate-producing organisms could amplify aryl hydrocarbon receptor signalling in Bregs, strengthening their suppressive output, while a microbiome that skews myeloid interleukin-1 beta and interleukin-6 production could expand the interleukin-10-competent pool. Depending on the balance, this could either blunt the antitumour T cell response that checkpoint blockade seeks to unleash or, conversely, restrain the autoimmune inflammation that causes immune-related adverse events. The dual role of the interleukin-10 programme means that any intervention shifting Breg behaviour will have consequences on both sides of the therapeutic ledger.

The authors are explicit that risk accompanies opportunity. Donor screening excludes most candidates for faecal microbiota transplantation, reflecting the stringent filtering required before a donor sample is considered safe. Drug-resistant Escherichia coli bacteraemia has followed FMT in documented cases, a sobering reminder that live microbial products can cause invasive infection. Transmission of procarcinogenic bacteria also remains possible, raising the theoretical concern that a transplant intended to boost immunotherapy could inadvertently introduce organisms that promote carcinogenesis. These risks are specific rather than generic, and they underscore why the field has moved toward defined live biotherapeutics such as CBM588, which offer a more controllable microbial intervention than whole-stool transfer.

The review also carries implications for managing immune-related adverse events, the colitis, pneumonitis, hepatitis and other inflammatory toxicities that complicate checkpoint blockade. If Bregs induced by gut commensals limit these toxicities, then patients whose microbiomes fail to induce robust Breg responses might be disproportionately vulnerable to severe irAEs, while those with butyrate-rich, Breg-supporting microbial communities might tolerate therapy better but respond less well to it. Stratifying patients by microbial and Breg signatures before treatment could therefore identify who needs closer monitoring for toxicity and who might benefit from interventions that temporarily restrain regulatory circuits to enhance antitumour immunity.

Patel and Middleton’s synthesis ultimately reframes the microbiome’s role in cancer immunotherapy as a B cell story waiting to be told. Much of the existing literature has focused on T cells, dendritic cells and myeloid populations when explaining why gut microbes modulate checkpoint inhibitor efficacy. By centring regulatory B cells and their dependence on microbial cytokine and metabolite cues, the review identifies a concrete, mechanistically grounded cell type through which diet, probiotics, FMT and even antibiotics might be rationally deployed. The four gaps the authors define, from Breg trafficking to the lung tumour microenvironment to the metabolic sustenance of human tumour Bregs, provide a research agenda that is deliberately testable. As microbiome-targeted therapeutics move from small trials toward standard oncology practice, understanding whether the Breg arm of immunity is the conduit through which microbes exert their clinical effects will be essential to harnessing the benefit while containing the risk.

Subject of Research: How the microbiome regulates B cells to influence checkpoint blockade immunotherapy in cancer

Article Title: Regulatory B cells and the microbiome: implications for checkpoint blockade therapy in cancer

Article References: Patel, A. J., & Middleton, G. W. (2026). Regulatory B cells and the microbiome: implications for checkpoint blockade therapy in cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04563-0

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04563-0

Keywords: regulatory B cells, microbiome, checkpoint blockade, cancer immunotherapy, gut-lung axis, interleukin-10, short-chain fatty acids, butyrate, faecal microbiota transplantation, immune-related adverse events, non-small cell lung cancer, tumour immunology

Acute pancreatitis is a sudden inflammation of the pancreas that ranges from a brief, self-limiting illness to a catastrophic, multi-organ failure. Severe acute pancreatitis, or SAP, carries a substantial risk of death, and clinicians have long observed that patients with obesity fare markedly worse. Excess white adipose tissue is not a passive energy store; it is metabolically active and densely populated with macrophages, the scavenger immune cells that can either fuel inflammation or resolve it. In obesity, the fat depots surrounding and infiltrating the pancreas become a reservoir of inflammatory signaling, and leaked fatty acids can poison pancreatic tissue directly. Understanding why obesity amplifies pancreatic injury, and how to interrupt that process, has become a pressing question in gastroenterology and intensive care.

The Xiamen team approached the problem from an unusual angle: the microbial communities living in the mouth and the gut. The researchers first mined public microbiome datasets from patients with acute pancreatitis, comparing those with obesity to those without. The comparison revealed that the oral microbiota of obese patients with pancreatitis was distinctly enriched, with computational functional prediction pointing to heightened activity in ubiquinol biosynthesis and lipid-related metabolic pathways. In other words, the microbial ecosystems of obese and non-obese patients were not just different in composition but potentially different in what they were doing biochemically, setting the stage for the team’s animal experiments.

To test causality, the researchers turned to a mouse model of diet-induced obesity. One group of mice was fed a high-fat diet until they became obese, while controls ate a normal diet; both were then induced to develop severe acute pancreatitis. The results were stark. Obese mice suffered significantly worse pancreatic and lung injury than their lean counterparts, confirming that obesity actively aggravates the disease rather than merely correlating with it. Deep sequencing of fecal samples showed that obesity also reshaped the gut microbiota, reducing its alpha diversity, a standard measure of ecological richness that is frequently lower in inflammatory and metabolic disease. Meanwhile, metabolomic profiling of epididymal white adipose tissue revealed that the metabolite landscape inside the fat itself had shifted dramatically in obese animals with pancreatitis.

The pivotal step came when the team integrated the two datasets. Correlation analyses linking the gut microbiome to the adipose tissue metabolome uncovered meaningful associations between specific microbial patterns and specific fat-derived metabolites, suggesting that gut microbes and fat chemistry are in conversation during severe pancreatitis. This gut-fat axis, the researchers reasoned, might be a lever that could be pulled therapeutically. Enter metformin. When obese mice with severe pancreatitis were treated with the drug, the consequences were unmistakable: pancreatic and lung injury were reduced, and the animals’ inflammatory burden eased compared with untreated obese controls.

How was a diabetes drug calming a pancreatic storm? The answer, at least in part, lay in the immune cells embedded in fat. Using flow cytometry, the team showed that metformin promoted M2 polarization of adipose tissue macrophages, shifting these cells from a pro-inflammatory, tissue-damaging phenotype toward an anti-inflammatory, repair-oriented one. Immunohistochemistry backed this up at the tissue level: levels of interleukin-10, a signature anti-inflammatory cytokine produced by M2 macrophages, rose in both the pancreas and the white adipose tissue of treated animals. In effect, metformin appeared to recruit the fat’s own immune residents to the side of resolution rather than destruction.

The metabolomic data offered a concrete candidate for the messenger. Metformin treatment significantly altered the composition of the gut microbiota, though notably it did not restore alpha diversity, and it modified obesity-associated changes in fat metabolites that were tied to the microbiome. Two metabolites stood out as upregulated: hexanoylcarnitine, an acylcarnitine with microbial associations, and isomaltose, a disaccharide sugar. To determine whether hexanoylcarnitine was merely a bystander or an active player, the researchers moved to the culture dish. They modeled pancreatitis-like conditions in RAW264.7 macrophage cells by treating them with lipopolysaccharide, a bacterial toxin, together with palmitic acid, a saturated fatty acid abundant in obese adipose tissue. When they then added L-hexanoylcarnitine to these stressed cells, the macrophages shifted toward the M2 phenotype, showing increased expression of Pparg mRNA, a master transcriptional regulator of M2 identity, and elevated levels of CD206, a canonical M2 surface protein.

That single experiment ties the whole story together into a coherent, if still preliminary, mechanistic chain. Obesity disrupts the gut microbiota and rewrites the metabolite profile of white adipose tissue, worsening pancreatic and lung injury in severe pancreatitis. Metformin intervenes by further remodeling the microbial community, which raises levels of microbe-associated hexanoylcarnitine, and that metabolite in turn pushes adipose tissue macrophages into their anti-inflammatory M2 state, boosting interleukin-10 and damping tissue damage. It is a striking illustration of how a drug’s benefits can travel through an ecosystem rather than a single molecular target, and it reframes the fat depot not just as a victim of inflammation but as a modifiable immune organ.

The caveats deserve equal emphasis. The mouse findings come from a diet-induced model, and the human data were limited to reanalyzed public microbiome datasets rather than a prospective clinical trial of metformin in obese patients with pancreatitis. Macrophage behavior in cultured RAW264.7 cells, while informative, does not capture the full complexity of living adipose tissue. The authors are transparent that their work identifies a potential mechanism, not a validated therapy, and metformin is not currently an established treatment for acute pancreatitis in any patient group. Clinical translation would require carefully designed trials in obese patients at high risk of severe disease, with attention to dosing, timing, and the gastrointestinal tolerability issues that can complicate metformin use in acutely ill people.

Even so, the study’s implications are hard to ignore. Metformin is inexpensive, generically available, and already taken by hundreds of millions of people worldwide, with a long safety record and a growing portfolio of proposed anti-inflammatory effects. If the gut-microbiota-to-adipose-macrophage pathway described here holds up in humans, it could open a rational route to protecting a vulnerable patient population from one of pancreatology’s worst outcomes, using a drug that costs pennies. It also adds to a broader shift in biomedical thinking: the recognition that metabolites produced in dialogue with our microbial residents can act as chemical instructions for the immune system. In this study, one such instruction, hexanoylcarnitine, told fat-resident macrophages to stand down. For patients with obesity facing severe acute pancreatitis, learning to send that message deliberately could one day make the difference between recovery and catastrophe.

Subject of Research: Metformin, gut microbiota-derived metabolites, and adipose tissue macrophage polarization in obesity-related severe acute pancreatitis

Article Title: Metformin ameliorates injury in obesity-related severe acute pancreatitis and modulates a gut microbiota-associated metabolite that promotes M2 polarization of adipose tissue macrophages

Article References: Guo, X.-W., Sui, Y.-C., Zhang, J.-Y., Hao, Y., Li, J., & Sheng, L.-P. (2026). Metformin ameliorates injury in obesity-related severe acute pancreatitis and modulates a gut microbiota-associated metabolite that promotes M2 polarization of adipose tissue macrophages. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08993-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08993-3

Keywords: metformin, severe acute pancreatitis, obesity, gut microbiota, adipose tissue macrophages, M2 polarization, hexanoylcarnitine, metabolomics, interleukin-10, white adipose tissue, inflammation, Journal of Translational Medicine

The central trick of NOCAGE lies in a single, carefully chosen amino acid. Many proteins depend on a glutamate residue at a catalytic or structural hotspot; remove or alter that glutamate and the protein loses its activity. The researchers substituted this essential glutamate with a synthetic, non-canonical amino acid whose side chain is chemically masked by a caging group. In this caged state, the protein folds normally but remains functionally silent, because the residue cannot perform its usual role. When the masked amino acid encounters nitric oxide, a chemical reaction strips away the cage, regenerating the native glutamate and switching the protein back on. In effect, the researchers have built a molecular tripwire: the protein stays dormant everywhere except where inflammation has raised nitric oxide levels.

Getting this synthetic amino acid into proteins required overcoming a classic challenge in chemical biology. Non-canonical amino acids are incorporated into proteins through genetic code expansion, a technique that repurposes an orthogonal aminoacyl-tRNA synthetase and tRNA pair to read a stop codon as an instruction to insert the unnatural residue. The team engineered a nitric oxide-responsive synthetase, which they named NorERS, through directed evolution from a pyrrolysyl-tRNA synthetase scaffold. Using fluorescence-activated cell sorting to screen large libraries, they selected variants that efficiently and specifically incorporated the caged glutamate, which they call NorE, into proteins in both bacterial and mammalian cells. Intact protein mass spectrometry confirmed that the incorporation was faithful, and iterative rounds of error-prone PCR mutagenesis and screening pushed the incorporation efficiency to levels comparable with well-established systems.

The chemistry of the caging group itself was equally deliberate. The researchers evaluated several ortho-phthalaldehyde-based caging groups and found that a methoxy-substituted variant reacted with nitric oxide with remarkable efficiency, achieving roughly 95 percent decaging conversion in the presence of a nitric oxide donor. Crucially, the caged amino acid proved resistant to a battery of other reactive oxygen and nitrogen species, physiologically relevant ions, metabolites, serum, and even liver homogenates. This selectivity matters enormously: an inflammation-triggered drug would be useless if it were accidentally activated by hydrogen peroxide or superoxide elsewhere in the body. The team also showed that activation works across a physiologically relevant range of pH values and in the presence of abundant biological nucleophiles such as glutathione, underscoring the robustness of the design.

To demonstrate the breadth of the platform, the researchers applied NOCAGE to an unusually diverse set of proteins. They engineered a nitric oxide-responsive antibody fragment, a luciferase enzyme, the anti-inflammatory cytokine interleukin-10, a bacterial toxin, and viral capsids from adeno-associated virus. In each case, the same logic applied: identify a glutamate or similar residue essential for binding or catalysis, replace it with the caged amino acid, and watch function collapse until nitric oxide restores it. An engineered anti-GFP nanobody lost its binding ability entirely until nitric oxide treatment restored it, and an engineered version of the drug antibody adalimumab, which neutralizes tumor necrosis factor-alpha, was similarly silenced and then reactivated. Even proteins lacking a suitable glutamate could be adapted, because the team extended the approach to caged aspartic acid and showed that substitutions at serine or other positions could also confer nitric oxide responsiveness.

The in vivo experiments are where the strategy reveals its therapeutic ambition. In mouse models of acute liver inflammation induced by lipopolysaccharide, an engineered nitric oxide-responsive luciferase called NO-Rluc lit up specifically in inflamed livers while remaining dark in healthy tissue, providing a real-time readout of nitric oxide production in living animals. Longitudinal imaging tracked the activation of the probe over hours following injection, and blocking nitric oxide synthase with the inhibitor L-NMMA suppressed the signal, confirming that the bioluminescence genuinely reported endogenous nitric oxide rather than an off-target effect. Such inflammation-localized imaging could eventually allow clinicians to visualize where inflammatory activity is concentrated in a patient’s body without invasive biopsies.

The therapeutic implications go beyond imaging. An engineered version of interleukin-10, a cytokine with powerful anti-inflammatory effects that has historically caused systemic side effects in clinical trials, was silenced by NOCAGE and reactivated only in inflamed tissue. In mice with lipopolysaccharide-induced systemic inflammation, the caged cytokine reduced tumor necrosis factor-alpha and interleukin-6 levels, and in a model of chemically induced colitis it ameliorated disease while limiting off-target activity. The team also engineered a nitric oxide-responsive version of Pseudomonas exotoxin A fused to an anti-HER2 nanobody, a construct relevant to cancer therapy, in which toxicity was suppressed until nitric oxide unmasked the catalytic glutamate. Safety evaluations, including cell viability assays across multiple cell lines and four-week dosing studies in mice with serum chemistry and histopathology of major organs, showed no detectable toxicity attributable to the caged proteins themselves.

Gene delivery represents another striking application. Adeno-associated virus vectors are the workhorses of gene therapy, but they transduce cells indiscriminately, which can cause unwanted expression in healthy tissue. By caging a conserved glutamate at position 563 in the AAV2 capsid, the researchers created viral particles that could only infect cells in nitric oxide-rich environments. In mice with inflamed livers, the engineered capsids delivered their genetic payload selectively to inflamed tissue, while wild-type capsids transduced without such discrimination. Sensitivity assays showed dose-dependent activation across a range of nitric oxide concentrations, and the modified vectors showed no increase in neutralizing antibody responses in treated animals. A capsid-based trigger of this kind could one day allow gene therapies to be aimed precisely at diseased, inflamed tissue while sparing the rest of the body.

Perhaps the most imaginative application is diagnostic. The researchers equipped the probiotic bacterium Escherichia coli Nissle, a strain with a long history of safe human use, with a gene encoding the nitric oxide-responsive luciferase. When these engineered biosensors were administered to mice, they produced a luminescent signal only upon encountering nitric oxide in the gut, enabling non-invasive detection of intestinal inflammation in a model of inflammatory bowel disease. Because luminescence from deep tissue is difficult to detect directly, the system’s sensitivity, demonstrated as several-hundred-fold signal increases upon nitric oxide exposure in bacterial cultures, offers a path toward swallowable or implantable living diagnostics that report the chemical state of the gut from the inside.

The authors, including co-first authors Wenkang Cai, Junhao Cui and Zhiying Zeng, describe NOCAGE as a generalizable method for post-translational control of protein function, and the evidence supports that claim. By converting a hallmark inflammatory molecule into a universal activation key, the platform unifies protein therapeutics, gene delivery and biosensing under a single chemical logic. Patent applications covering the technology have been filed by Peking University, and the work was funded by the National Natural Science Foundation of China and related programs. Considerable work remains before caged proteins reach the clinic, including studies of pharmacokinetics, immunogenicity and the nitric oxide thresholds of human disease tissue. But the conceptual advance is clear: proteins can now be engineered to listen for inflammation and respond on cue, opening a route to medicines that act only where and when the body signals that they are needed.

Subject of Research: Engineering nitric oxide-responsive proteins using caged non-canonical amino acids for inflammation-targeted activation

Article Title: Engineering inflammation-responsive proteins through nitric oxide-caged amino acids

Article References: Cai, W., Cui, J., Zeng, Z., Xiang, Z., Xie, Y., Su, Y., Zuo, Y., Liu, Y., Wang, H., Chang, L., Wang, X., Wang, J., Ma, J.-A., & Liu, T. (2026). Engineering inflammation-responsive proteins through nitric oxide-caged amino acids. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01782-9

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01782-9

Keywords: nitric oxide, protein engineering, genetic code expansion, non-canonical amino acids, inflammation, NOCAGE, gene delivery, AAV capsids, biosensors, interleukin-10, inflammatory bowel disease, post-translational control

The research team, led by Egle Milasauskiene of the Laboratory of Behavioral Medicine at the Lithuanian University of Health Sciences, with collaborators including Guy C. Brown of the University of Cambridge, set out to address a persistent gap. Immune dysregulation and gut-derived inflammation have been implicated in a subset of patients with depression for years, yet their diagnostic usefulness across different levels of illness severity, and their sensitivity to psychotropic treatment, remained unclear. To probe these questions, the investigators quantified LPS and four cytokines—TNF-alpha, interleukin-6, interleukin-10, and interferon-gamma—in the circulation of participants, and assessed depression severity using the Montgomery–Åsberg Depression Rating Scale, stratifying patients into mild-to-moderate and severe groups.

The headline result was a clear divergence in inflammatory profiles. Compared with healthy controls, patients with major depressive disorder showed elevated LPS and TNF-alpha and reduced interleukin-10, an anti-inflammatory cytokine, while interleukin-6 and interferon-gamma did not differ between the groups. Crucially, the elevation of LPS was specific to patients with mild-to-moderate depression, whereas TNF-alpha was raised across all severity levels. This pattern suggests that translocation of bacterial products from the gut into the bloodstream may be a feature of earlier or less severe stages of the illness, while a more systemic pro-inflammatory state, driven by TNF-alpha, accompanies greater severity.

From a technical standpoint, the diagnostic potential of these markers was assessed using receiver operating characteristic analysis, which quantifies how well a biomarker or combination of biomarkers separates cases from controls. A combined model incorporating LPS, TNF-alpha, and interleukin-10 achieved the highest diagnostic accuracy for major depressive disorder overall, with an area under the curve of 0.778, and performed even better for mild-to-moderate disease, reaching an AUC of 0.818. For severe depression, TNF-alpha alone was the strongest predictor, with an AUC of 0.677, while LPS alone distinguished mild-to-moderate from severe depression with an AUC of 0.679. These values, while not yet in the range of a standalone clinical test, indicate meaningful discriminatory power for markers that can be measured in a routine blood sample.

Importantly, the associations survived rigorous statistical scrutiny. The researchers adjusted their analyses for age, sex, body mass index, smoking status, and psychotropic medication use, and the links between the biomarkers and depression severity remained significant. This matters because confounders such as smoking and obesity are known to influence inflammatory markers, and because antidepressants and other psychotropic drugs could theoretically alter immune signaling. By demonstrating that the LPS and cytokine patterns hold after adjustment, the study strengthens the case that these molecules reflect genuine disease-related biology rather than artifacts of lifestyle or treatment.

That said, medication was not biologically inert in the data. LPS levels were higher among patients with mild-to-moderate depression who were receiving antidepressant monotherapy, and lower among those on combination therapy, regardless of severity. The authors interpret this cautiously, noting that the cross-sectional design cannot determine whether combination treatment suppresses gut-derived inflammation or whether patients on combination regimens differed in other relevant ways. Even so, the observation raises the intriguing possibility that certain pharmacological strategies may dampen bacterial translocation from the gut, and that treatment effects on inflammatory biomarkers could one day inform the choice of therapeutic regimen.

The conceptual payoff of the study lies in its subdivision of depression. Mild-to-moderate major depressive disorder, in this framework, is associated with elevated LPS, reflecting gut-derived inflammation and potentially constituting a distinct biological subtype, whereas severe depression is linked to TNF-alpha-driven inflammation. If replicated, this dichotomy could reshape how researchers and clinicians think about the heterogeneity of depression. Instead of treating all patients as having a single illness with variable intensity, biomarker profiles might identify mechanistically distinct subgroups—those whose symptoms are tied to intestinal barrier dysfunction and endotoxin leakage, and those whose illness is dominated by systemic cytokine activity.

Such a framework has therapeutic implications. A patient subgroup characterized by gut-derived inflammation might respond to interventions targeting the intestinal barrier or the microbiome, ranging from dietary strategies to anti-inflammatory agents, while a TNF-alpha-dominated subgroup might be more plausibly matched to immunomodulatory treatments, some of which are already being explored in treatment-resistant depression. The authors suggest that these biomarkers may aid in distinguishing depression subtypes and informing targeted therapeutic strategies, a vision that aligns with the broader push toward precision psychiatry, in which laboratory measures complement clinical interviews in guiding care.

The study also carries caveats typical of cross-sectional research. Blood samples capture a single moment in time, so the findings cannot establish whether elevated LPS precedes the onset of mild-to-moderate depression or results from it, nor can they track how biomarkers fluctuate as illness waxes and wanes. The sample, drawn from a single region and registered on ClinicalTrials.gov, will need replication in larger and more diverse cohorts before LPS and cytokine panels can be proposed for clinical use. The diagnostic accuracies reported, while statistically robust, remain below the thresholds generally demanded of a standalone screening test, positioning these markers as components of a multi-marker panel rather than definitive diagnostics.

Nevertheless, the work adds momentum to a growing body of evidence linking the gut, the immune system, and the brain in psychiatric illness. By showing that the direction and composition of inflammatory signaling differ systematically with depression severity, the Lithuanian-Cambridge collaboration offers both a practical lead—blood-based markers that track disease subtypes—and a mechanistic hypothesis: that a leaky gut may help fuel a recognizable form of depression, while deeper illness engages a different inflammatory engine. For a disorder that lacks established biological markers, that is a consequential step, and one that future longitudinal and interventional studies will be eager to test.

Subject of Research: Circulating lipopolysaccharide and cytokine levels as severity-dependent biomarkers in major depressive disorder

Article Title: Lipopolysaccharide and cytokine levels differ by disease severity in major depressive disorder

Article References: Milasauskiene, E., Burkauskas, J., Jesmanas, S., Gleizniene, R., Borutaite, V., Raskauskiene, N., Skemiene, K., Adomaitiene, V., Gradauskiene, B., Brown, G. C., & Steibliene, V. (2026). Lipopolysaccharide and cytokine levels differ by disease severity in major depressive disorder. Discover Mental Health. https://doi.org/10.1007/s44192-026-00587-1

Image Credits: AI Generated

DOI: 10.1007/s44192-026-00587-1

Keywords: major depressive disorder, lipopolysaccharide, endotoxin, cytokines, TNF-alpha, interleukin-10, inflammation, gut-derived inflammation, biomarkers, depression severity, immune dysregulation, precision psychiatry